Team:Fatih-Medical/Testpage

From 2012.igem.org

(Difference between revisions)
 
(13 intermediate revisions not shown)
Line 1: Line 1:
{{Template:Fatih-header}}
{{Template:Fatih-header}}
<html>
<html>
 +
<style>
<style>
-
#top-section { visibility: hidden; }
+
#top-section { display: none; }
-
#content {width:100%; padding:0px; }
+
#content {width:100%; padding:0px; background: none; border: none; }
-
#footer-box {visibility: hidden; height: 0px; padding: 0px; margin: 0px }
+
#footer-box { display: none; }
-
#catlinks {visibility: hidden; height: 0px; padding: 0px; margin: 0px }
+
#catlinks {display: none; }
 +
.firstHeading {display: none; }
 +
#contentSub {margin: 0px; }
 +
div#bodyContent p {margin: 0px; }
</style>
</style>
 +
<div class="bg">
<div class="bg">
Line 13: Line 18:
<header>
<header>
     <div class="main">
     <div class="main">
-
         <h1><a href="index.html">StarCorp</a></h1>
+
         <h1><a href="index.html">Fatih Medical</a></h1>
         <ul class="icons">
         <ul class="icons">
-
             <li><a class="normatip" title="Twitter" href="more.html"><img src="https://static.igem.org/mediawiki/2012/d/df/Fatih-Icon1.png" alt=""></a></li>
+
             <li><a class="normatip" title="Twitter" href="http://twitter.com/FatihMedical"><img src="https://static.igem.org/mediawiki/2012/d/df/Fatih-Icon1.png" alt=""></a></li>
-
             <li><a class="normatip" title="Rss" href="more.html"><img src="https://static.igem.org/mediawiki/2012/c/cb/Fatih-Icon2.png" alt=""></a></li>
+
             <li><a class="normatip" title="Fecebook" href="http://www.facebook.com/FatihMedical"><img src="https://static.igem.org/mediawiki/2012/d/d8/Fatih-Icon3.png" alt=""></a></li>
-
            <li><a class="normatip" title="Fecebook" href="more.html"><img src="https://static.igem.org/mediawiki/2012/d/d8/Fatih-Icon3.png" alt=""></a></li>
+
         </ul>
         </ul>
     <nav>
     <nav>
             <ul class="sf-menu">
             <ul class="sf-menu">
-
                 <li class="current"><a href="index.html">About us</a><ul>
+
                 <li class="current"><a href="https://2012.igem.org/Team:Fatih-Medical">Home</a></li>
-
                        <li><a href="more.html">Company</a><ul>
+
                <li><a href="https://2012.igem.org/Team:Fatih-Medical/Team">Team</a></li>
-
                                <li><a href="more.html">Our Team</a></li>
+
                <li><a href="https://2012.igem.org/Team:Fatih-Medical/Anket">Anket</a></li>
-
                                <li><a href="more.html">What We Do</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Fatih-Medical/Project">Project</a></li>
-
                            </ul>
+
                 <li><a href="https://2012.igem.org/Team:Fatih-Medical/Modeling">Modeling</a></li>
-
                        </li>
+
                 <li><a href="https://2012.igem.org/Team:Fatih-Medical/Notebook">Notebook</a></li>
-
                        <li><a href="more.html">Latest News</a></li>
+
                 <li><a href="https://2012.igem.org/Team:Fatih-Medical/Safety">Safety</a></li>          
-
                        <li><a href="more.html">Contacts</a></li>
+
-
                    </ul>
+
-
                </li>
+
-
                <li><a href="index-1.html">Services</a></li>
+
-
                 <li><a href="index-2.html">Solutions</a></li>
+
-
                 <li><a href="index-3.html">Support</a></li>
+
-
                 <li><a href="index-4.html">Training</a></li>
+
-
                 <li><a href="index-5.html">Contacts</a></li>
+
             </ul>
             </ul>
             <div class="bottom"></div>
             <div class="bottom"></div>
Line 45: Line 41:
     <div class="content_2">
     <div class="content_2">
-
<h1><font size="5">CANCEL the CANCER: A SynBio Approach to the Early Diagnosis of Cancer </font>
 
-
<HR size="10" width="70%" align="left">
 
-
<BR>
 
-
  Our project is mainly based on the early diagnosis of cancer. EpCAM (Epithelial cell adhesion molecule) is a pan-epithelial differentiation antigen overexpressed on the basolateral surface of most carcinomas and Circulating Tumor Cells(CTC); cells which are released into blood in early phases of cancer. Our objective is to fix appropriate antibodies for EpCAM antigens to the E.coli cell wall so that we will be able to detect CTCs before the cancer precipitates its way to metastasis. For the next step, we plan to enhance the detection signal in our bacteria by the means of the quorum sensing mechanism. Finally, to prevent the production of possible undesirable and detrimental genetically modified organisms (GMOs), we aim to induce self-destruction device in our E.coli via emission of light.
 
-
 
 
-
<BR>
 
-
<BR>
 
-
<BR>
 
-
<BR>
 
-
</h1>
 
<!--==============================content================================-->
<!--==============================content================================-->
-
<!--
+
<section id="content_fatih">
-
<section id="content">
+
     <div class="container_24">
     <div class="container_24">
         <div class="wrapper">
         <div class="wrapper">
 +
         <article class="grid_8">
         <article class="grid_8">
             <div class="padding-left">
             <div class="padding-left">
-
                 <div class="block">
+
                 <h2>CANCEL the CANCER: A SynBio Approach to the Early Diagnosis of Cancer </h2>
-
                    <strong>Target</strong> Marketing
+
<HR size="10" width="70%" align="left">
-
                        <a href="more.html"></a>
+
 
-
                    </div>
+
 
-
                <div class="block">
+
-
                    <strong>Market</strong> Research
+
-
                        <a href="more.html"></a>
+
-
                    </div>
+
-
                <div class="block">
+
-
                    <strong>Powerful</strong> Analytics
+
-
                        <a href="more.html"></a>
+
-
                    </div>
+
-
                <div class="block">
+
-
                    <strong>Business</strong>  Strategies
+
-
                        <a href="more.html"></a>
+
-
                    </div>
+
                 </div>
                 </div>
             </article>
             </article>
 +
             <article class="grid_15">
             <article class="grid_15">
-
            <h1>Welcome</h1>
+
  Our project is mainly based on the early diagnosis of cancer. EpCAM (Epithelial cell adhesion molecule) is a pan-epithelial differentiation antigen overexpressed on the basolateral surface of most carcinomas and Circulating Tumor Cells(CTC); cells which are released into blood in early phases of cancer. Our objective is to fix appropriate antibodies for EpCAM antigens to the E.coli cell wall so that we will be able to detect CTCs before the cancer precipitates its way to metastasis. For the next step, we plan to enhance the detection signal in our bacteria by the means of the quorum sensing mechanism. Finally, to prevent the production of possible undesirable and detrimental genetically modified organisms (GMOs), we aim to induce self-destruction device in our E.coli via emission of light.
-
                <p>Duis aute irure dolor in reprehendeit invoptate sit nvelit esse cillum dolore fumgiat officia desemrunt mollit. Anim in laborum excepteur sint occaecat.</p>
+
 
-
                <p class="border-bot"><a href="more.html">Duis aute irure dolor in repreheder invoptate</a> velit cillum dolore inugiat officia deserunt molit anim in laborum excepteur sint occaiecat cupidatan oin proident. Sunt in culpa qui officia deserunt.ollit anim.</p>
+
-
                <h2>Best Services for You!</h2>
+
-
                <div class="wrapper border-bot1">
+
-
                <figure class="img-indent"><a class="lightbox-image" data-gal="prettyPhoto[1]" href="images/page1-img1-big.jpg"><img class="radius" src="images/page1-img1.jpg" alt=""></a></figure>
+
-
                    <div class="extra-wrap">
+
-
                    <h4>Market Assessment</h4>
+
-
                        <p class="p1">Duis aute irure dolor in reprehendeit invoptate sit nvelit esse cillum dolore fumgiat officia desemrunt mollit laborum.</p>
+
-
                        <a class="button" href="more.html">Learn More</a>
+
-
                    </div>
+
-
                </div>
+
-
                <div class="wrapper border-bot1">
+
-
                <figure class="img-indent"><a class="lightbox-image" data-gal="prettyPhoto[1]" href="images/page1-img2-big.jpg"><img class="radius" src="images/page1-img2.jpg" alt=""></a></figure>
+
-
                    <div class="extra-wrap">
+
-
                    <h4>Business Planning</h4>
+
-
                        <p class="p1">Duis aute irure dolor in reprehendeit invoptate sit nvelit esse cillum dolore fumgiat officia desemrunt mollit laborum.</p>
+
-
                        <a class="button" href="more.html">Learn More</a>
+
-
                    </div>
+
-
                </div>
+
-
                <div class="wrapper">
+
-
                <figure class="img-indent"><a class="lightbox-image" data-gal="prettyPhoto[1]" href="images/page1-img3-big.jpg"><img class="radius" src="images/page1-img3.jpg" alt=""></a></figure>
+
-
                    <div class="extra-wrap">
+
-
                    <h4>Support Center</h4>
+
-
                        <p class="p1">Duis aute irure dolor in reprehendeit invoptate sit nvelit esse cillum dolore fumgiat officia desemrunt mollit laborum.</p>
+
-
                        <a class="button" href="more.html">Learn More</a>
+
-
                    </div>
+
-
                </div>
+
             </article>
             </article>
 +
 +
 +
         </div>
         </div>
     </div>
     </div>
</section>
</section>
-
-->
 
Line 121: Line 72:
</div>
</div>
</div>
</div>
-
<ul id="mycarousel" class="jcarousel-skin-tango">
+
 
-
    <li><a href="more.html"><img src="images/carousel-banner1.jpg" alt=""></a></li>
+
-
    <li><a href="more.html"><img src="images/carousel-banner2.jpg" alt=""></a></li>
+
-
    <li><a href="more.html"><img src="images/carousel-banner3.jpg" alt=""></a></li>
+
-
    <li><a href="more.html"><img src="images/carousel-banner4.jpg" alt=""></a></li>
+
-
</ul>
+
<aside>
<aside>
<div class="container_24">
<div class="container_24">
Line 134: Line 80:
                     <h3>Best Services</h3>
                     <h3>Best Services</h3>
                     <ul>
                     <ul>
-
                         <li><a href="more.html">Market Research</a></li>
+
                         <li><a href="/Team:Fatih-Medical">Home</a></li>
-
                         <li><a href="more.html">Online Banking</a></li>
+
                         <li><a href="/Team:Fatih-Medical/Team">Team</a></li>
-
                         <li><a href="more.html">Financial Services</a></li>
+
                         <li><a href="/Team:Fatih-Medical/Anket">Anket</a></li>
-
                         <li><a href="more.html">Client Network Solutions</a></li>
+
                         <li><a href="/Team:Fatih-Medical/Project">Project</a></li>
-
                         <li><a href="more.html">Business Help</a></li>
+
                         <li><a href="/Team:Fatih-Medical/Parts">Parts Submitted to the Registry</a></li>
                     </ul>
                     </ul>
                 </div>
                 </div>
Line 145: Line 91:
             <h3>Popular Items</h3>
             <h3>Popular Items</h3>
                 <ul>
                 <ul>
-
                 <li><a href="more.html">Solutions &amp; Training</a></li>
+
                 <li><a href="/Team:Fatih-Medical/Modeling">Modeling</a></li>
-
                 <li><a href="more.html">Affiliate Program</a></li>
+
                 <li><a href="/Team:Fatih-Medical/Notebook">Notebook</a></li>
-
                 <li><a href="more.html">Production</a></li>
+
                 <li><a href="/Team:Fatih-Medical/Safety">Safety</a></li>
-
                 <li><a href="more.html">Risk Management</a></li>
+
                 <li><a href="/Team:Fatih-Medical/Attributions">Attributions</a></li>
-
                 <li><a href="more.html">Consultation</a></li>
+
                 <li><a href="/Team:Fatih-Medical/Survey">Survey</a></li>
                 </ul>
                 </ul>
             </article>
             </article>
Line 165: Line 111:
<div class="main">
<div class="main">
         <div class="fright"><!-- {%FOOTER_LINK} --></div>
         <div class="fright"><!-- {%FOOTER_LINK} --></div>
-
         StarCorp © 2011 &nbsp;| &nbsp;<a href="index-6.html">Privacy Policy</a>
+
         Fatih Medical © 2012 &nbsp;| &nbsp;<a href="index-6.html">Privacy Policy</a>
     </div>
     </div>
</footer>
</footer>
</body>
</body>
</html>
</html>

Latest revision as of 19:27, 11 September 2012

Fatih Medical

CANCEL the CANCER: A SynBio Approach to the Early Diagnosis of Cancer

Our project is mainly based on the early diagnosis of cancer. EpCAM (Epithelial cell adhesion molecule) is a pan-epithelial differentiation antigen overexpressed on the basolateral surface of most carcinomas and Circulating Tumor Cells(CTC); cells which are released into blood in early phases of cancer. Our objective is to fix appropriate antibodies for EpCAM antigens to the E.coli cell wall so that we will be able to detect CTCs before the cancer precipitates its way to metastasis. For the next step, we plan to enhance the detection signal in our bacteria by the means of the quorum sensing mechanism. Finally, to prevent the production of possible undesirable and detrimental genetically modified organisms (GMOs), we aim to induce self-destruction device in our E.coli via emission of light.

Retrieved from "http://2012.igem.org/Team:Fatih-Medical/Testpage"